Skip to main content
Top
Published in: Endocrine Pathology 1/2015

01-03-2015

Expression of MUC1 and CD176 (Thomsen-Friedenreich antigen) in Papillary Thyroid Carcinomas

Authors: Xiang-xiang Zhan, Bing Zhao, Chang Diao, Yi Cao, Ruo-chuan Cheng

Published in: Endocrine Pathology | Issue 1/2015

Login to get access

Abstract

The incidence of thyroid cancer has appeared as an increasing trend globally, especially in Asian countries. In this study, the expression of mucin-1 (MUC1) and Thomsen-Friedenreich antigen, Galβ1-3GalNAcα1-R (CD176) was investigated by immunohistochemistry in papillary thyroid carcinomas (PTCs), which accounts for approximately 80 % of all thyroid cancer. We found that 78 % of PTC overexpressed MUC1. Importantly, we observed firstly that CD176 was expressed in 63 % of PTC, but was faintly or not expressed in normal thyroid tissues and benign thyroid disease tissues, indicating that CD176 is also a tumour-associated antigen for PTCs. Moreover, expression of CD176 was strongly correlated with MUC1 by immunohistochemical staining in PTCs. Furthermore, we used the immunochemical method to confirm that MUC1 is a common and main carrier of CD176 in PTCs. Our data demonstrated that MUC1 and CD176 might be promising biomarkers for thyroid cancer.
Literature
1.
go back to reference Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:2164–2167, 2006.CrossRefPubMed Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:2164–2167, 2006.CrossRefPubMed
2.
go back to reference Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol 11:1093–1097, 2004.CrossRefPubMed Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol 11:1093–1097, 2004.CrossRefPubMed
3.
go back to reference Haselkorn T, Bernstein L, Preston-Martin S, Cozen W, Mack WJ. Descriptive epidemiology of thyroid cancer in Los Angeles County, 1972–1995. Cancer Causes Control 11:163–170, 2000.CrossRefPubMed Haselkorn T, Bernstein L, Preston-Martin S, Cozen W, Mack WJ. Descriptive epidemiology of thyroid cancer in Los Angeles County, 1972–1995. Cancer Causes Control 11:163–170, 2000.CrossRefPubMed
4.
go back to reference Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid 16:47–53, 2006.CrossRefPubMed Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid 16:47–53, 2006.CrossRefPubMed
5.
go back to reference Hayes DF, Zurawski VR, Kufe DW. Comparison of circulating CA15-3 and carcinoembryonic antigen in patients with breast cancer. J Clin Oncol 4:1542–1550, 1986.PubMed Hayes DF, Zurawski VR, Kufe DW. Comparison of circulating CA15-3 and carcinoembryonic antigen in patients with breast cancer. J Clin Oncol 4:1542–1550, 1986.PubMed
6.
go back to reference Safi F, Kohler I, Rottinger E, Berger H-G. The value of the tumour marker CA153-3 in diagnosing and monitoring breast cancer. Cancer 68:574–582, 1991.CrossRefPubMed Safi F, Kohler I, Rottinger E, Berger H-G. The value of the tumour marker CA153-3 in diagnosing and monitoring breast cancer. Cancer 68:574–582, 1991.CrossRefPubMed
7.
go back to reference Siragusa M, Zerilli M, Iovino F, et al. MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Cancer Res 67:5522–5530, 2007.CrossRefPubMed Siragusa M, Zerilli M, Iovino F, et al. MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Cancer Res 67:5522–5530, 2007.CrossRefPubMed
8.
go back to reference Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol Ther 6: 481–486, 2007.CrossRefPubMed Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol Ther 6: 481–486, 2007.CrossRefPubMed
9.
go back to reference Beatty PL, Finn OJ. Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas. Ann N Y Acad Sci 1284:52–56, 2013.CrossRefPubMed Beatty PL, Finn OJ. Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas. Ann N Y Acad Sci 1284:52–56, 2013.CrossRefPubMed
10.
go back to reference Wreesmann VB, Sieczka EM, Socci ND, et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64: 3780–3789, 2004.CrossRefPubMed Wreesmann VB, Sieczka EM, Socci ND, et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64: 3780–3789, 2004.CrossRefPubMed
11.
go back to reference Patel KN, Maghami E, Wreesmann VB, Shaha AR, Shah JP. Ghossein R, Singh B. MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas. Surgery 138: 994–1001, 2005.CrossRefPubMedCentralPubMed Patel KN, Maghami E, Wreesmann VB, Shaha AR, Shah JP. Ghossein R, Singh B. MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas. Surgery 138: 994–1001, 2005.CrossRefPubMedCentralPubMed
12.
go back to reference Morari EC, Silva JR, Guilhen AC, et al. Muc-1 expression may help characterize thyroid nodules but does not predict patients’ outcome. Endocr Pathol 21: 242–249, 2010.CrossRefPubMed Morari EC, Silva JR, Guilhen AC, et al. Muc-1 expression may help characterize thyroid nodules but does not predict patients’ outcome. Endocr Pathol 21: 242–249, 2010.CrossRefPubMed
13.
go back to reference Baek SK, Woo JS, Kwon SY, Lee SH, Chae YS, Jung KY. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma. Laryngoscope 117: 911–916, 2007.CrossRefPubMed Baek SK, Woo JS, Kwon SY, Lee SH, Chae YS, Jung KY. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma. Laryngoscope 117: 911–916, 2007.CrossRefPubMed
14.
go back to reference Weiss M, Baruch A, Keydar I, Wreschner DH. Preoperative diagnosis of thyroid papillary carcinoma by reverse transcriptase polymerase chain reaction of the MUC1 gene. Int J Cancer 66:55–59, 1996.CrossRefPubMed Weiss M, Baruch A, Keydar I, Wreschner DH. Preoperative diagnosis of thyroid papillary carcinoma by reverse transcriptase polymerase chain reaction of the MUC1 gene. Int J Cancer 66:55–59, 1996.CrossRefPubMed
15.
go back to reference Abrosimov A, Saenko V, Meirmanov S, et al. The cytoplasmic expression of MUC1 in papillary thyroid carcinoma of different histologicalvariants and its correlation with cyclin D1 overexpression. Endocr Pathol 18: 68–75, 2007.CrossRefPubMed Abrosimov A, Saenko V, Meirmanov S, et al. The cytoplasmic expression of MUC1 in papillary thyroid carcinoma of different histologicalvariants and its correlation with cyclin D1 overexpression. Endocr Pathol 18: 68–75, 2007.CrossRefPubMed
16.
go back to reference Magro G, Schiappacassi M, Perissinotto D, Corsaro A, et al. Differential expression of mucins 1–6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ. J Pathol 200: 357–369, 2003.CrossRefPubMed Magro G, Schiappacassi M, Perissinotto D, Corsaro A, et al. Differential expression of mucins 1–6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ. J Pathol 200: 357–369, 2003.CrossRefPubMed
17.
go back to reference Fan XN, Karsten U, Goletz S, Cao Y. Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol Res Pract 206:585–589, 2010.CrossRefPubMed Fan XN, Karsten U, Goletz S, Cao Y. Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol Res Pract 206:585–589, 2010.CrossRefPubMed
18.
go back to reference He F, Li H, Li WS, Dong XH. Expression of mucin-l and beta-catenin in papillary thyroid carcinoma and the clinical significance thereof. Zhong Hua Yi Xue Za Zhi 82:257–261, 2002. He F, Li H, Li WS, Dong XH. Expression of mucin-l and beta-catenin in papillary thyroid carcinoma and the clinical significance thereof. Zhong Hua Yi Xue Za Zhi 82:257–261, 2002.
19.
go back to reference Renaud F, Gnemmi V, Devos P, Aubert S, et al. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse. Thyroid 24: 1375–1384, 2014.CrossRefPubMed Renaud F, Gnemmi V, Devos P, Aubert S, et al. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse. Thyroid 24: 1375–1384, 2014.CrossRefPubMed
20.
go back to reference Bieche I, Ruffet E, Zweibaum Abet et al. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid. Thyroid 7: 725–731, 1997.CrossRefPubMed Bieche I, Ruffet E, Zweibaum Abet et al. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid. Thyroid 7: 725–731, 1997.CrossRefPubMed
21.
22.
go back to reference Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV, Hilkens J. Cell-associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem 267: 6171–6177, 1992.PubMed Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV, Hilkens J. Cell-associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem 267: 6171–6177, 1992.PubMed
23.
go back to reference Cao Y, Blohm D, Ghadimi BM, Karsten U et al. Mucins (MUC1 and MUC3) of gastrointestinal and breast epithelia reveal different and heterologous tumour associated aberrations in glycosylation. J Histochem Cytochem 45:1547–1557, 1997.CrossRefPubMed Cao Y, Blohm D, Ghadimi BM, Karsten U et al. Mucins (MUC1 and MUC3) of gastrointestinal and breast epithelia reveal different and heterologous tumour associated aberrations in glycosylation. J Histochem Cytochem 45:1547–1557, 1997.CrossRefPubMed
24.
go back to reference Cao Y, Schlag PM, Karsten U. Immunodetection of epithelial mucin (MUC1, MUC3) and mucin-associated glycotopes (TF, Tn, and sialosyl-Tn) in benign and malignant lesions of colonic epithelium: apolar localization corresponds to malignant transformation. Virchows Arch 431:159–166, 1997.CrossRefPubMed Cao Y, Schlag PM, Karsten U. Immunodetection of epithelial mucin (MUC1, MUC3) and mucin-associated glycotopes (TF, Tn, and sialosyl-Tn) in benign and malignant lesions of colonic epithelium: apolar localization corresponds to malignant transformation. Virchows Arch 431:159–166, 1997.CrossRefPubMed
25.
go back to reference Goletz S, Cao Y, Danielcyk A, Ravn P, Schoeber U and Karsten U. Thomsen-Friedenreich antigen: the ‘hidden’ tumour antigen. Adv Exp Med Biol 535: 147–162, 2003.CrossRefPubMed Goletz S, Cao Y, Danielcyk A, Ravn P, Schoeber U and Karsten U. Thomsen-Friedenreich antigen: the ‘hidden’ tumour antigen. Adv Exp Med Biol 535: 147–162, 2003.CrossRefPubMed
26.
go back to reference Cao Y, Merling A, Karsten U, Schwartz-Albiez R. Expression of Thomsen-Friedenreich-related carbohydrate antigens on human leukemia cells. In: Leucocyte Typing VII (eds. D. Mason et al.), Oxford University Press, Oxford, 204–205, 2002. Cao Y, Merling A, Karsten U, Schwartz-Albiez R. Expression of Thomsen-Friedenreich-related carbohydrate antigens on human leukemia cells. In: Leucocyte Typing VII (eds. D. Mason et al.), Oxford University Press, Oxford, 204–205, 2002.
27.
go back to reference Cao Y, Stosiek P, Springer GF and Karsten U. Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem Cell Biol 106:197–207, 1996.CrossRefPubMed Cao Y, Stosiek P, Springer GF and Karsten U. Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem Cell Biol 106:197–207, 1996.CrossRefPubMed
28.
go back to reference Springer GF. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med 75: 594–602, 1997.CrossRefPubMed Springer GF. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med 75: 594–602, 1997.CrossRefPubMed
29.
go back to reference Lin WM, Karsten U, Goletz S, Cheng RC, Cao Y. Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells. Int J Exp Pathol 92:97–105, 2011.CrossRefPubMedCentralPubMed Lin WM, Karsten U, Goletz S, Cheng RC, Cao Y. Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells. Int J Exp Pathol 92:97–105, 2011.CrossRefPubMedCentralPubMed
30.
go back to reference Cao Y, Karsten UR, Liebrich W, Haensch W, Springer GF and Schlag PM. Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas, a reevaluation. Cancer 76: 1700–1708, 1995.CrossRefPubMed Cao Y, Karsten UR, Liebrich W, Haensch W, Springer GF and Schlag PM. Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas, a reevaluation. Cancer 76: 1700–1708, 1995.CrossRefPubMed
31.
go back to reference Glinsky VV, Glinsky GV, Rittenhouse-Olson K, et al. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 61:4851–4857, 2001.PubMed Glinsky VV, Glinsky GV, Rittenhouse-Olson K, et al. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 61:4851–4857, 2001.PubMed
32.
go back to reference Heimburg J, Yan J, Morey S, et al. Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia 8: 939–948, 2006.CrossRefPubMedCentralPubMed Heimburg J, Yan J, Morey S, et al. Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia 8: 939–948, 2006.CrossRefPubMedCentralPubMed
33.
go back to reference Yi B, Zhang M, Schwartz-Albiez R, Cao Y. Mechanisms of the apoptosis induced by CD176 antibody on human leukemic cells. Int J Oncol 38:1565–1573, 2011.PubMed Yi B, Zhang M, Schwartz-Albiez R, Cao Y. Mechanisms of the apoptosis induced by CD176 antibody on human leukemic cells. Int J Oncol 38:1565–1573, 2011.PubMed
34.
go back to reference Yi B, Zhang Z, Zhang M, Schwartz-Albiez R, Cao Y. CD176 (Thomsen-Friedenreich antigen) anti-serum treatment leads to a therapeutic response in a murine model of leukemia. Oncol Rep 30:1841–1847, 2013.PubMed Yi B, Zhang Z, Zhang M, Schwartz-Albiez R, Cao Y. CD176 (Thomsen-Friedenreich antigen) anti-serum treatment leads to a therapeutic response in a murine model of leukemia. Oncol Rep 30:1841–1847, 2013.PubMed
35.
go back to reference Watson T. Outlook lung cancer: immunotherapy—chemical tricks. Nature 513:S10–S11, 2014.CrossRef Watson T. Outlook lung cancer: immunotherapy—chemical tricks. Nature 513:S10–S11, 2014.CrossRef
36.
go back to reference Cao Y, Karsten U, Otto G, Bannasch P. Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and 2,6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions. Virchows Arch 434:503–509, 1999.CrossRefPubMed Cao Y, Karsten U, Otto G, Bannasch P. Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and 2,6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions. Virchows Arch 434:503–509, 1999.CrossRefPubMed
37.
go back to reference Cao Y, Merling A, Karsten U, Goletz S, Punzel M, Butschak G, Schwartz-Albiez R. Expression of CD175 (Tn), CD175s (sialosyl-Tn), and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells. Int J Cancer 123: 89–99, 2008.CrossRefPubMed Cao Y, Merling A, Karsten U, Goletz S, Punzel M, Butschak G, Schwartz-Albiez R. Expression of CD175 (Tn), CD175s (sialosyl-Tn), and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells. Int J Cancer 123: 89–99, 2008.CrossRefPubMed
38.
go back to reference Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of HBME-1, galectin-3, CK19 and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 126:700–708, 2006.CrossRefPubMed Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of HBME-1, galectin-3, CK19 and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 126:700–708, 2006.CrossRefPubMed
39.
go back to reference Baldus SE, Hanisch F-G, Kotlarek GM, Zirbes TK, Thiele J, Isenberg J, Karsten UR, Devine PL, Dienes HP. Coexpression of MUC1 mucin peptide core and the Thomsen-Friedenreich antigen in colorectal neoplasms. Cancer 82: 1019–1027, 1998.CrossRefPubMed Baldus SE, Hanisch F-G, Kotlarek GM, Zirbes TK, Thiele J, Isenberg J, Karsten UR, Devine PL, Dienes HP. Coexpression of MUC1 mucin peptide core and the Thomsen-Friedenreich antigen in colorectal neoplasms. Cancer 82: 1019–1027, 1998.CrossRefPubMed
Metadata
Title
Expression of MUC1 and CD176 (Thomsen-Friedenreich antigen) in Papillary Thyroid Carcinomas
Authors
Xiang-xiang Zhan
Bing Zhao
Chang Diao
Yi Cao
Ruo-chuan Cheng
Publication date
01-03-2015
Publisher
Springer US
Published in
Endocrine Pathology / Issue 1/2015
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-015-9356-9

Other articles of this Issue 1/2015

Endocrine Pathology 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.